Taipei, Taiwan and Ahmedabad, India, 11th December 2023 -- Leading global pharmaceutical companies, Lotus Pharmaceutical (1795:TT) and Intas Pharmaceuticals, Ltd. announced today that they have entered into a partnership, to distribute and commercialize denosumab biosimilar in South Korea, Taiwan and multiple markets in Southeast Asia.
'Denosumab' is a monoclonal antibody that is widely recognized for its efficacy in averting bone fractures and enhancing bone density among those grappling with osteoporosis, marketed under trade name Prolia®. Another brand of denosumab i.e. Xgeva® is designated for preventing skeletal-related events in individuals with multiple myeloma and those with bone metastases from solid tumors. Xgeva® also stands as a therapeutic solution for giant cell tumors of bone in cases where surgical resection is impractical or likely to lead to severe morbidity.
According to IQVIA data, the annual sales for Prolia® for the 12 months ended Dec 2022 was approximately USD 202 million and for Xgeva® was approximately USD 45 million in the regions covered in the agreement.
Petar Vazharov, Lotus' Chief Executive Officer said, "We are thrilled to join forces with Intas to bring denosumab to our Asian territories. This transaction is in line with strengthening our portfolio for osteoporosis and postmenopausal women’s health and oncology. This strategic acquisition not only fortifies our portfolio for oncology and women's health but also underscores our commitment to making high quality complex, biosimilar products accessible to those who need it most. Furthermore, we are poised to leverage our extensive experience and expertise in registering and commercializing biosimilars and innovative products within the specified therapeutic classes, ensuring a comprehensive approach to healthcare solutions.”
Binish Chudgar, Intas’ Vice-Chairman & Managing Director said, "We are delighted to partner with Lotus in this significant collaboration. This strategic alliance underscores our advanced capabilities in manufacturing world-class, complex, and innovative biosimilars, aligning seamlessly with our vision to provide global access to these cutting-edge products. This commitment also highlights our dedication to advancing global healthcare solutions, particularly in critical therapeutic areas such as osteoporosis, postmenopausal women’s health, and oncology, to make a positive impact on the lives of patients in need."
Marc Comas, Executive Vice President at Intas B2B said, “We are delighted to strengthen our current alliance with Lotus Pharmaceutical with the addition of the first biosimilar to the partnership. This collaboration will further consolidate Intas Pharmaceuticals as a supplier in the region, providing access to high-quality and affordable medicines for patients which contributes to make a positive impact on their lives.”
According to the terms of the agreement, Lotus will possess commercialization rights in the applicable territory and will assume responsibility for the regulatory approval process. This territory encompasses Taiwan, South Korea and multiple markets in Southeast Asia. Intas is responsible for completing development as well as manufacturing and supply.
For the full release please visit https://www.lotuspharm.com/
